{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 205409, "items": [{"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T21:20:52Z", "timestamp": 1575321652256}, "reference-count": 37, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "35", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2008, 12, 10]]}, "abstract": "<jats:sec><jats:title>Purpose</jats:title><jats:p> Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized that, in KRAS wild-type patients, BRAF mutations could have a predictive/prognostic value. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We retrospectively analyzed objective tumor responses, time to progression, overall survival (OS), and the mutational status of KRAS and BRAF in 113 tumors from cetuximab- or panitumumab-treated metastatic CRC patients. The effect of the BRAF V600E mutation on cetuximab or panitumumab response was also assessed using cellular models of CRC. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> KRAS mutations were present in 30% of the patients and were associated with resistance to cetuximab or panitumumab (P = .011). The BRAF V600E mutation was detected in 11 of 79 patients who had wild-type KRAS. None of the BRAF-mutated patients responded to treatment, whereas none of the responders carried BRAF mutations (P = .029). BRAF-mutated patients had significantly shorter progression-free survival (P = .011) and OS (P &lt; .0001) than wild-type patients. In CRC cells, the introduction of BRAF V600E allele impaired the therapeutic effect of cetuximab or panitumumab. Treatment with the BRAF inhibitor sorafenib restored sensitivity to panitumumab or cetuximab of CRC cells carrying the V600E allele. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment. Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CRC patients carrying the V600E oncogenic mutation. </jats:p></jats:sec>", "DOI": "10.1200/jco.2008.18.0786", "type": "journal-article", "created": {"date-parts": [[2008, 11, 11]], "date-time": "2008-11-11T02:37:27Z", "timestamp": 1226371047000}, "page": "5705-5712", "source": "Crossref", "is-referenced-by-count": 962, "title": ["Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer"], "prefix": "10.1200", "volume": "26", "author": [{"given": "Federica", "family": "Di Nicolantonio", "sequence": "first", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Miriam", "family": "Martini", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Francesca", "family": "Molinari", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Andrea", "family": "Sartore-Bianchi", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Sabrina", "family": "Arena", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Piercarlo", "family": "Saletti", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Sara", "family": "De Dosso", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Luca", "family": "Mazzucchelli", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Milo", "family": "Frattini", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Salvatore", "family": "Siena", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}, {"given": "Alberto", "family": "Bardelli", "sequence": "additional", "affiliation": [{"name": "From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca\u2019 Granda; Italian Foundation for Cancer Research\u2013Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.18.0786", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T20:12:13Z", "timestamp": 1574885533000}, "score": 60.409786, "issued": {"date-parts": [[2008, 12, 10]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[2008, 12, 10]]}, "issue": "35"}, "alternative-id": ["10.1200/JCO.2008.18.0786"], "URL": "http://dx.doi.org/10.1200/jco.2008.18.0786", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T19:38:12Z", "timestamp": 1575315492788}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "12", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2008, 10, 1]], "date-time": "2008-10-01T00:00:00Z", "timestamp": 1222819200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2008, 10]]}, "DOI": "10.1016/s1359-6349(08)72181-5", "type": "journal-article", "created": {"date-parts": [[2008, 10, 22]], "date-time": "2008-10-22T09:48:37Z", "timestamp": 1224668917000}, "page": "81", "source": "Crossref", "is-referenced-by-count": 2, "title": ["247 ORAL BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer"], "prefix": "10.1016", "volume": "6", "author": [{"given": "F.", "family": "Di Nicolantonio", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Martini", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Molinari", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Sartore Bianchi", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Arena", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Saletti", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Mazzucchelli", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Frattini", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Siena", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Bardelli", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634908721815?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634908721815?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 24]], "date-time": "2018-12-24T23:50:10Z", "timestamp": 1545695410000}, "score": 48.244358, "issued": {"date-parts": [[2008, 10]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 10]]}, "issue": "12"}, "alternative-id": ["S1359634908721815"], "URL": "http://dx.doi.org/10.1016/s1359-6349(08)72181-5", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:16:27Z", "timestamp": 1574745387389}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_6", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 10]]}, "DOI": "10.1093/annonc/mdw370.49", "type": "journal-article", "created": {"date-parts": [[2017, 2, 3]], "date-time": "2017-02-03T17:29:14Z", "timestamp": 1486142954000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease"], "prefix": "10.1093", "volume": "27", "author": [{"given": "F.", "family": "Rivera", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Peeters", "sequence": "additional", "affiliation": []}, {"given": "J-Y.", "family": "Douillard", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Taieb", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Koukakis", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Demonty", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Siena", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2016, 10, 11]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/27/suppl_6/501P/19450122/mdw370.49.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 9]], "date-time": "2017-08-09T05:32:10Z", "timestamp": 1502256730000}, "score": 42.46788, "issued": {"date-parts": [[2016, 10]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 10, 11]]}, "published-print": {"date-parts": [[2016, 10]]}, "issue": "suppl_6"}, "URL": "http://dx.doi.org/10.1093/annonc/mdw370.49", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T05:19:34Z", "timestamp": 1575523174084}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "Supplement_5", "license": [{"URL": "https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model", "start": {"date-parts": [[2019, 10, 1]], "date-time": "2019-10-01T00:00:00Z", "timestamp": 1569888000000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019, 10, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>In Italy, previously untreated patients with RAS wild-type metastatic colorectal cancer (mCRC) may receive an epidermal growth factor receptor (EGFR) inhibitor with a chemotherapy regimen (CT). The choice of anti-EGFR, either cetuximab (cet+CT) or panitumumab (pan+CT), depends on various factors, including adverse event (AE) profiles. Although AE profiles will evolve with increasing use and familiarity, the differences in AE profiles can be explored using literature and safety data from the summary of product characteristics (SmPC). The financial impact of these differences on the Italian National Health Service has yet to be estimated.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>We developed a model to estimate costs of AE management. Frequencies of common and very common AEs associated with cet+CT or pan+CT were sourced from the respective SmPC.1,2 Applicable resource use costs were obtained from hospital services price lists from the Ministry of Health using the DRG outpatient tariff.3 The national-level financial impact was calculated from the number of cet+CT\u2013eligible patients with mCRC treated in the first line based on published literature, national guidelines, and pan+CT market share. Inputs were validated by practicing Italian oncologists.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>All-grade AEs were estimated to be 58.1% lower and grade 3/4 AEs were estimated to be 70.2% lower in patients receiving cet+CT than in those receiving pan+CT. Mean costs of AE management per patient treated with cet+CT and pan+CT were estimated at \u20ac1,194 and \u20ac2,951, respectively, resulting in average savings of \u20ac1,758 (59.6%) per patient. Differences are mainly driven by a lower frequency of AEs that are costly to manage, such as GI disorders. Annual savings could reach \u20ac2,191,839 for a population of 1,247 cet+CT\u2013eligible patients with mCRC.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>Fewer AEs for cet+CT may result in markedly lower AE management costs vs pan+CT. Although results should be considered together with overall costs and clinical outcomes, cet+CT could decrease cost burden on the Italian National Health Service and AE burden for patients with mCRC.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Editorial acknowledgement</jats:title>\n                  <jats:p>ClinicalThinking, Inc, Hamilton, NJ, USA (funded by Merck Healthcare KGaA, Darmstadt, Germany).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Legal entity responsible for the study</jats:title>\n                  <jats:p>Merck Healthcare KGaA.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Funding</jats:title>\n                  <jats:p>Merck Healthcare KGaA.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosure</jats:title>\n                  <jats:p>N. Personeni: Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Serono. V. Gebbia: Honoraria (self): Merck; Honoraria (self): Amgen; Honoraria (self): Roche. P. Novelli: Full / Part-time employment: Merck Serono S.p.A. S. Di Matteo: Research grant / Funding (institution): Merck. G. Colombo: Research grant / Funding (institution): Merck. C. Pescott: Full / Part-time employment: Merck Healthcare KGaA. All other authors have declared no conflicts of interest.</jats:p>\n               </jats:sec>", "DOI": "10.1093/annonc/mdz246.073", "type": "journal-article", "created": {"date-parts": [[2019, 10, 1]], "date-time": "2019-10-01T07:18:55Z", "timestamp": 1569914335000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["596PThe cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective"], "prefix": "10.1093", "volume": "30", "author": [{"given": "K", "family": "Patterson", "sequence": "first", "affiliation": [{"name": "Health Economics, BresMed, Sheffield, UK"}]}, {"given": "S", "family": "Bhattacharyya", "sequence": "additional", "affiliation": [{"name": "Health Economics, BresMed, Sheffield, UK"}]}, {"given": "N", "family": "Personeni", "sequence": "additional", "affiliation": [{"name": "Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}]}, {"given": "V", "family": "Gebbia", "sequence": "additional", "affiliation": [{"name": "University of Palermo, La Maddalena Hospital, Palermo, Italy"}]}, {"given": "P", "family": "Novelli", "sequence": "additional", "affiliation": [{"name": "HTA & Market Access, Merck Serono S.p.A., Rome, Italy"}]}, {"given": "S Di", "family": "Matteo", "sequence": "additional", "affiliation": [{"name": "Health Economics and Outcomes Research, S.A.V.E. Studi Analisi Valutazioni Economiche srl, Milan, Italy"}]}, {"given": "G", "family": "Colombo", "sequence": "additional", "affiliation": [{"name": "Department of Drug Sciences, University of Pavia, Pavia, Italy"}]}, {"given": "C", "family": "Pescott", "sequence": "additional", "affiliation": [{"name": "Global Evidence and Value Development, Merck Healthcare KGaA, Darmstadt, Germany"}]}], "member": "286", "published-online": {"date-parts": [[2019, 10, 1]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz246.073/30084288/mdz246.073.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 1]], "date-time": "2019-10-01T07:18:56Z", "timestamp": 1569914336000}, "score": 39.570747, "issued": {"date-parts": [[2019, 10, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2019, 10, 1]]}, "published-print": {"date-parts": [[2019, 10, 1]]}, "issue": "Supplement_5"}, "URL": "http://dx.doi.org/10.1093/annonc/mdz246.073", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}], "subject": ["Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:17:03Z", "timestamp": 1574745423574}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_9", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 12]]}, "DOI": "10.1093/annonc/mdw581.028", "type": "journal-article", "created": {"date-parts": [[2017, 2, 3]], "date-time": "2017-02-03T18:49:34Z", "timestamp": 1486147774000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["195P Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third-line in daily practice"], "prefix": "10.1093", "volume": "27", "author": [{"given": "N.", "family": "Sugimoto", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Hasegawa", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Fujisawa", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Yoshinami", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Yagi", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Imamura", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2016, 12, 20]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/27/suppl_9/mdw581.028/10241812/mdw581.028.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 24]], "date-time": "2017-08-24T18:10:55Z", "timestamp": 1503598255000}, "score": 39.437252, "issued": {"date-parts": [[2016, 12]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 12, 20]]}, "published-print": {"date-parts": [[2016, 12]]}, "issue": "suppl_9"}, "URL": "http://dx.doi.org/10.1093/annonc/mdw581.028", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T00:02:51Z", "timestamp": 1576800171947}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "4_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2012, 2, 1]]}, "abstract": "<jats:p> 640 </jats:p><jats:p> Background: In British Columbia, use of anti-EGFR therapy for KRAS wt MCRC is limited to patients (pts) previously treated with both irinotecan and oxaliplatin. Physicians may choose either Pmab monotherapy or Cmab/Iri combination therapy. We sought to compare the characteristics and outcomes of all pts treated with Pmab/Cmab referred to 5 provincial cancer centers since July, 2009. </jats:p><jats:p> Methods: Eligible patients received at least one dose of either Pmab (6mg/kg q2w) or Cetuximab (500mg/m2 q2w) plus Iri (180mg/m2 q2w). Baseline characteristics and systemic therapy were prospectively collected, while ECOG and metastatectomy status were retrospectively collected. Kaplan-Meier survival analysis was conducted from the first day of Pmab/Cmab. </jats:p><jats:p> Results: Among 178 eligible pts, Pmab was chosen 3 times more often than Cmab/Iri (see table). Pts treated with Cmab/Iri were significantly younger and had better performance status than those treated with Pmab. There were no statistically significant differences in other prognostic variables, and a similar proportion received chemotherapy after Pmab vs. Cmab/Iri. Overall survival was slightly longer among patients receiving Cmab/Iri (8.3 mo), vs. Pmab (7.7 mo) (p=.03). </jats:p><jats:p> Conclusions: Pmab was chosen more often than Cmab/Iri for similarly eligible patients. Cmab/Iri pts were younger, were more likely to have ECOG performance status 0/1 and achieved a modestly longer overall survival. Either regimen appears to be suitable for previously treated pts with KRAS wt MCRC. </jats:p><jats:p> [Table: see text] </jats:p>", "DOI": "10.1200/jco.2012.30.4_suppl.640", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T18:52:39Z", "timestamp": 1487875959000}, "page": "640-640", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC)."], "prefix": "10.1200", "volume": "30", "author": [{"given": "Hagen F.", "family": "Kennecke", "sequence": "first", "affiliation": [{"name": "British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada"}]}, {"given": "Leo", "family": "Chen", "sequence": "additional", "affiliation": [{"name": "British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada"}]}, {"given": "C. D.", "family": "Blanke", "sequence": "additional", "affiliation": [{"name": "British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada"}]}, {"given": "Winson Y.", "family": "Cheung", "sequence": "additional", "affiliation": [{"name": "British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada"}]}, {"given": "Kimberly", "family": "Schaff", "sequence": "additional", "affiliation": [{"name": "British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada"}]}, {"given": "Caroline", "family": "Speers", "sequence": "additional", "affiliation": [{"name": "British Columbia Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2012.30.4_suppl.640", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:57:33Z", "timestamp": 1574891853000}, "score": 38.291576, "issued": {"date-parts": [[2012, 2, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2012, 2, 1]]}, "issue": "4_suppl"}, "alternative-id": ["10.1200/jco.2012.30.4_suppl.640"], "URL": "http://dx.doi.org/10.1200/jco.2012.30.4_suppl.640", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:16:38Z", "timestamp": 1574745398621}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_4", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014, 9]]}, "DOI": "10.1093/annonc/mdu296.2", "type": "journal-article", "created": {"date-parts": [[2017, 2, 3]], "date-time": "2017-02-03T17:36:04Z", "timestamp": 1486143364000}, "page": "iv12-iv12", "source": "Crossref", "is-referenced-by-count": 0, "title": ["29INEMERGING DRUGGABLE TARGETS IN COLORECTAL CANCER"], "prefix": "10.1093", "volume": "25", "author": [{"given": "F.", "family": "Di Nicolantonio", "sequence": "first", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2014, 9]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/25/suppl_4/iv12/9689183/mdu296.2.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 24]], "date-time": "2017-08-24T10:04:01Z", "timestamp": 1503569041000}, "score": 38.235996, "issued": {"date-parts": [[2014, 9]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2014, 9]]}, "published-print": {"date-parts": [[2014, 9]]}, "issue": "suppl_4"}, "URL": "http://dx.doi.org/10.1093/annonc/mdu296.2", "ISSN": ["1569-8041", "0923-7534"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:15:42Z", "timestamp": 1574745342890}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_6", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 10]]}, "DOI": "10.1093/annonc/mdw370.30", "type": "journal-article", "created": {"date-parts": [[2017, 2, 3]], "date-time": "2017-02-03T17:09:59Z", "timestamp": 1486141799000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 \u00b1 panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study"], "prefix": "10.1093", "volume": "27", "author": [{"given": "J.", "family": "Taieb", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Peeters", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Siena", "sequence": "additional", "affiliation": []}, {"given": "F. Rivera", "family": "Herrero", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Koukakis", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Demonty", "sequence": "additional", "affiliation": []}, {"given": "J-Y.", "family": "Douillard", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2016, 10, 11]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/27/suppl_6/482P/19450084/mdw370.30.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 9]], "date-time": "2017-08-09T05:31:20Z", "timestamp": 1502256680000}, "score": 38.166904, "issued": {"date-parts": [[2016, 10]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 10, 11]]}, "published-print": {"date-parts": [[2016, 10]]}, "issue": "suppl_6"}, "URL": "http://dx.doi.org/10.1093/annonc/mdw370.30", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:48:14Z", "timestamp": 1574891294106}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_8", "license": [{"URL": "https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model", "start": {"date-parts": [[2018, 10, 23]], "date-time": "2018-10-23T00:00:00Z", "timestamp": 1540252800000}, "delay-in-days": 22, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2018, 10, 1]]}, "DOI": "10.1093/annonc/mdy281.159", "type": "journal-article", "created": {"date-parts": [[2018, 10, 23]], "date-time": "2018-10-23T07:25:50Z", "timestamp": 1540279550000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["614TiPUCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis"], "prefix": "10.1093", "volume": "29", "author": [{"given": "T", "family": "Mazard", "sequence": "first", "affiliation": [{"name": "Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, France"}]}, {"given": "F", "family": "Ghiringhelli", "sequence": "additional", "affiliation": [{"name": "Medical Oncology Unit, Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"}]}, {"given": "C", "family": "Mollevi", "sequence": "additional", "affiliation": [{"name": "Biometry Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, France"}]}, {"given": "E", "family": "Assenat", "sequence": "additional", "affiliation": [{"name": "Medical Oncology, CHU Saint Eloi, Montpellier, France"}]}, {"given": "C", "family": "Gavoille", "sequence": "additional", "affiliation": [{"name": "Oncology Department, Institut de Canc\u00e9rologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, France"}]}, {"given": "D", "family": "Smith", "sequence": "additional", "affiliation": [{"name": "Service d'Oncologie, CHU Bordeaux Hopital St. Andr\u00e9, Bordeaux, France"}]}, {"given": "V", "family": "Pezzella", "sequence": "additional", "affiliation": [{"name": "R&D \u2013 UCGI Group, UNICANCER, Paris, France"}]}, {"given": "R", "family": "Meddeb", "sequence": "additional", "affiliation": [{"name": "Integrative Cancer Research for Personalized Medecine in Digestive Oncology, IRCM, Montpellier, France"}]}, {"given": "B", "family": "Pastor", "sequence": "additional", "affiliation": [{"name": "Integrative Cancer Research for Personalized Medecine in Digestive Oncology, IRCM, Montpellier, France"}]}, {"given": "M", "family": "Ychou", "sequence": "additional", "affiliation": [{"name": "Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, France"}]}, {"given": "A R", "family": "Thierry", "sequence": "additional", "affiliation": [{"name": "Integrative Cancer Research for Personalized Medecine in Digestive Oncology, IRCM, Montpellier, France"}]}], "member": "286", "published-online": {"date-parts": [[2018, 10, 23]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy281.159/26138210/mdy281.159.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 23]], "date-time": "2018-10-23T07:31:27Z", "timestamp": 1540279887000}, "score": 37.47226, "issued": {"date-parts": [[2018, 10, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2018, 10, 23]]}, "published-print": {"date-parts": [[2018, 10, 1]]}, "issue": "suppl_8"}, "URL": "http://dx.doi.org/10.1093/annonc/mdy281.159", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T15:29:13Z", "timestamp": 1575214153635}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2013, 6, 1]]}, "DOI": "10.1158/1078-0432.ccr-13-0339", "type": "journal-article", "created": {"date-parts": [[2013, 4, 24]], "date-time": "2013-04-24T01:18:56Z", "timestamp": 1366766336000}, "page": "2794-2796", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Mouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing?"], "prefix": "10.1158", "volume": "19", "author": [{"given": "F.", "family": "Di Nicolantonio", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Bardelli", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2013, 4, 23]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-13-0339", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T03:59:14Z", "timestamp": 1482465554000}, "score": 37.05098, "issued": {"date-parts": [[2013, 4, 23]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2013, 5, 30]]}, "published-print": {"date-parts": [[2013, 6, 1]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-13-0339", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T00:01:36Z", "timestamp": 1576800096353}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2011, 5, 20]]}, "DOI": "10.1200/jco.2011.29.15_suppl.e14123", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T18:58:03Z", "timestamp": 1487876283000}, "page": "e14123-e14123", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Individual KRAS mutations modulate response to targeted agents in colorectal cancer."], "prefix": "10.1200", "volume": "29", "author": [{"given": "A.", "family": "Bardelli", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Lamba", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Di Nicolantonio", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2011.29.15_suppl.e14123", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:26:49Z", "timestamp": 1574890009000}, "score": 36.50208, "issued": {"date-parts": [[2011, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2011, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2011.29.15_suppl.e14123"], "URL": "http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e14123", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T15:20:43Z", "timestamp": 1575559243753}, "reference-count": 0, "publisher": "Clarivate Analytics (US)", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Drugs Today"], "published-print": {"date-parts": [[2019]]}, "DOI": "10.1358/dot.2019.55.11.3035584", "type": "journal-article", "created": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T06:54:56Z", "timestamp": 1575356096000}, "page": "683", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer"], "prefix": "10.1358", "volume": "55", "author": [{"given": "F", "family": "Shahjehan", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Kamatham", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Chandrasekharan", "sequence": "additional", "affiliation": []}, {"given": "P.M.", "family": "Kasi", "sequence": "additional", "affiliation": []}], "member": "71", "container-title": ["Drugs of Today"], "language": "en", "deposited": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T06:54:56Z", "timestamp": 1575356096000}, "score": 36.2341, "issued": {"date-parts": [[2019]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2019]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1358/dot.2019.55.11.3035584", "ISSN": ["1699-3993"], "issn-type": [{"value": "1699-3993", "type": "print"}], "subject": ["Pharmacology (medical)", "Pharmacology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T19:59:37Z", "timestamp": 1574539177304}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2011, 4, 15]]}, "DOI": "10.1158/1538-7445.am2011-4130", "type": "proceedings-article", "created": {"date-parts": [[2014, 8, 14]], "date-time": "2014-08-14T22:32:54Z", "timestamp": 1408055574000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 4130: Signaling specificity by individual KRAS mutations modulate response to targeted agents in colorectal cancer"], "prefix": "10.1158", "author": [{"given": "Federica Di", "family": "Nicolantonio", "sequence": "first", "affiliation": []}, {"given": "Simona", "family": "Lamba", "sequence": "additional", "affiliation": []}, {"given": "Alberto", "family": "Bardelli", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 13]]}, "event": {"name": "Proceedings: AACR 102nd Annual Meeting 2011\u2010\u2010 Apr 2\u20106, 2011; Orlando, FL"}, "container-title": ["Clinical Research"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2011-4130", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T21:52:57Z", "timestamp": 1558216377000}, "score": 35.5896, "issued": {"date-parts": [[2011, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2011-4130"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2011-4130"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T06:07:31Z", "timestamp": 1574402851185}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 9, 1]], "date-time": "2011-09-01T00:00:00Z", "timestamp": 1314835200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2011, 9]]}, "DOI": "10.1016/s0959-8049(11)71776-2", "type": "journal-article", "created": {"date-parts": [[2011, 9, 26]], "date-time": "2011-09-26T09:33:43Z", "timestamp": 1317029623000}, "page": "S431", "source": "Crossref", "is-referenced-by-count": 0, "title": ["6131 POSTER Evaluation of BRAF Mutational Status in Wild Type (WT) KRAS Metastatic Colon-Rectal Cancer (MCRC) Patients (pts) Treated With Cetuximab (C) \u2013 a Single Institution Experience"], "prefix": "10.1016", "volume": "47", "author": [{"given": "M.E.", "family": "Cazzaniqa", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Baronchelli", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Bovo", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Pellizzoni", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Crosti", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Giuntini", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Villa", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Cortinovis", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Bidoli", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804911717762?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804911717762?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 29]], "date-time": "2018-11-29T21:26:20Z", "timestamp": 1543526780000}, "score": 35.43295, "issued": {"date-parts": [[2011, 9]]}, "references-count": 0, "alternative-id": ["S0959804911717762"], "URL": "http://dx.doi.org/10.1016/s0959-8049(11)71776-2", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T11:24:02Z", "timestamp": 1574508242130}, "reference-count": 37, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 3, 1]], "date-time": "2013-03-01T00:00:00Z", "timestamp": 1362096000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Colorectal Cancer"], "published-print": {"date-parts": [[2013, 3]]}, "DOI": "10.1016/j.clcc.2012.07.001", "type": "journal-article", "created": {"date-parts": [[2012, 10, 4]], "date-time": "2012-10-04T08:01:04Z", "timestamp": 1349337664000}, "page": "45-53", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab"], "prefix": "10.1016", "volume": "12", "author": [{"given": "Riccardo", "family": "Ricotta", "sequence": "first", "affiliation": []}, {"given": "Angelo", "family": "Vanzulli", "sequence": "additional", "affiliation": []}, {"given": "Mauro", "family": "Moroni", "sequence": "additional", "affiliation": []}, {"given": "Barbara", "family": "Colnago", "sequence": "additional", "affiliation": []}, {"given": "Matteo", "family": "Oriani", "sequence": "additional", "affiliation": []}, {"given": "Michele", "family": "Nichelatti", "sequence": "additional", "affiliation": []}, {"given": "Carolina", "family": "Sarnataro", "sequence": "additional", "affiliation": []}, {"given": "Filippo", "family": "Venturini", "sequence": "additional", "affiliation": []}, {"given": "Sara", "family": "Di Bella", "sequence": "additional", "affiliation": []}, {"given": "Martina", "family": "Maiolani", "sequence": "additional", "affiliation": []}, {"given": "Maria Olga", "family": "Giganti", "sequence": "additional", "affiliation": []}, {"given": "Andrea", "family": "Sartore-Bianchi", "sequence": "additional", "affiliation": []}, {"given": "Salvatore", "family": "Siena", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Colorectal Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1533002812001028?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1533002812001028?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 20]], "date-time": "2018-11-20T10:21:16Z", "timestamp": 1542709276000}, "score": 35.286476, "issued": {"date-parts": [[2013, 3]]}, "references-count": 37, "journal-issue": {"published-print": {"date-parts": [[2013, 3]]}, "issue": "1"}, "alternative-id": ["S1533002812001028"], "URL": "http://dx.doi.org/10.1016/j.clcc.2012.07.001", "ISSN": ["1533-0028"], "issn-type": [{"value": "1533-0028", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T08:59:59Z", "timestamp": 1575277199697}, "reference-count": 26, "publisher": "Informa UK Limited", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Biology & Therapy"], "published-print": {"date-parts": [[2013, 12]]}, "DOI": "10.4161/cbt.26343", "type": "journal-article", "created": {"date-parts": [[2013, 9, 17]], "date-time": "2013-09-17T20:56:18Z", "timestamp": 1379451378000}, "page": "1098-1103", "source": "Crossref", "is-referenced-by-count": 16, "title": ["Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens"], "prefix": "10.1080", "volume": "14", "author": [{"given": "Filippo", "family": "Pietrantonio", "sequence": "first", "affiliation": []}, {"given": "Federica", "family": "Perrone", "sequence": "additional", "affiliation": []}, {"given": "Pamela", "family": "Biondani", "sequence": "additional", "affiliation": []}, {"given": "Claudia", "family": "Maggi", "sequence": "additional", "affiliation": []}, {"given": "Andrea", "family": "Lampis", "sequence": "additional", "affiliation": []}, {"given": "Claudia", "family": "Bertan", "sequence": "additional", "affiliation": []}, {"given": "Filippo", "family": "Venturini", "sequence": "additional", "affiliation": []}, {"given": "Luca", "family": "Tondulli", "sequence": "additional", "affiliation": []}, {"given": "Daris", "family": "Ferrari", "sequence": "additional", "affiliation": []}, {"given": "Vincenzo", "family": "Ricci", "sequence": "additional", "affiliation": []}, {"given": "Federica", "family": "Villa", "sequence": "additional", "affiliation": []}, {"given": "Gloria", "family": "Barone", "sequence": "additional", "affiliation": []}, {"given": "Nadia", "family": "Bianco", "sequence": "additional", "affiliation": []}, {"given": "Antonio", "family": "Ghidini", "sequence": "additional", "affiliation": []}, {"given": "Ilaria", "family": "Bossi", "sequence": "additional", "affiliation": []}, {"given": "Giuseppe", "family": "Fanetti", "sequence": "additional", "affiliation": []}, {"given": "Maria", "family": "Di Bartolomeo", "sequence": "additional", "affiliation": []}, {"given": "Filippo", "family": "de Braud", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 10, 28]]}, "reference": [{"key": "R1", "DOI": "10.1056/NEJMoa071834", "doi-asserted-by": "publisher"}, {"key": "R2", "DOI": "10.1056/NEJMoa0805019", "doi-asserted-by": "publisher"}, {"key": "R3", "DOI": "10.1200/JCO.2009.27.4860", "doi-asserted-by": "publisher"}, {"key": "R4", "DOI": "10.1093/annonc/mdq632", "doi-asserted-by": "publisher"}, {"key": "R5", "DOI": "10.1200/JCO.2006.08.1620", "doi-asserted-by": "publisher"}, {"key": "R6", "DOI": "10.1200/JCO.2004.10.182", "doi-asserted-by": "publisher"}, {"key": "R7", "DOI": "10.1056/NEJMoa0804385", "doi-asserted-by": "publisher"}, {"key": "R8", "DOI": "10.1016/j.ejca.2012.02.057", "doi-asserted-by": "publisher"}, {"key": "R9", "DOI": "10.1200/JCO.2008.18.0786", "doi-asserted-by": "publisher"}, {"key": "R10", "DOI": "10.1016/S1470-2045(10)70130-3", "doi-asserted-by": "publisher"}, {"key": "R11", "DOI": "10.1093/annonc/mdn541", "doi-asserted-by": "publisher"}, {"key": "R12", "author": "Misale S", "volume": "486", "first-page": "532", "year": "2012", "journal-title": "Nature", "DOI": "10.1038/nature11156", "doi-asserted-by": "crossref"}, {"key": "R13", "DOI": "10.1016/j.bbagen.2007.11.003", "doi-asserted-by": "publisher"}, {"key": "R14", "DOI": "10.3816/CCC.2010.n.046", "doi-asserted-by": "publisher"}, {"key": "R15", "DOI": "10.1038/nm.2609", "doi-asserted-by": "publisher"}, {"key": "R16", "DOI": "10.1007/s00280-008-0831-6", "doi-asserted-by": "publisher"}, {"key": "R17", "DOI": "10.1634/theoncologist.2011-0452", "doi-asserted-by": "publisher"}, {"key": "R18", "author": "Metges J", "volume": "28", "first-page": "e14000", "year": "2010", "journal-title": "J Clin Oncol", "DOI": "10.1200/jco.2010.28.15_suppl.e14000", "doi-asserted-by": "crossref"}, {"key": "R19", "DOI": "10.1093/annonc/mdr623", "doi-asserted-by": "publisher"}, {"key": "R20", "DOI": "10.1158/1078-0432.CCR-10-3137", "doi-asserted-by": "publisher"}, {"key": "R21", "DOI": "10.1001/jama.2010.1535", "doi-asserted-by": "publisher"}, {"key": "R22", "DOI": "10.1200/JCO.2012.45.1492", "doi-asserted-by": "publisher"}, {"key": "R23", "DOI": "10.1002/cncr.26086", "doi-asserted-by": "publisher"}, {"key": "R24", "DOI": "10.1093/annonc/mdf034", "doi-asserted-by": "publisher"}, {"key": "R25", "DOI": "10.1016/j.ejca.2008.10.026", "doi-asserted-by": "publisher"}, {"key": "R26", "DOI": "10.1215/15228517-2009-003", "doi-asserted-by": "publisher"}], "container-title": ["Cancer Biology & Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.4161/cbt.26343", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 24]], "date-time": "2019-07-24T05:04:45Z", "timestamp": 1563944685000}, "score": 35.133377, "subtitle": ["Clinical outcome and biomarkers of efficacy"], "issued": {"date-parts": [[2013, 12]]}, "references-count": 26, "journal-issue": {"published-online": {"date-parts": [[2014, 10, 28]]}, "published-print": {"date-parts": [[2013, 12]]}, "issue": "12"}, "alternative-id": ["10.4161/cbt.26343"], "URL": "http://dx.doi.org/10.4161/cbt.26343", "relation": {"cites": []}, "ISSN": ["1538-4047", "1555-8576"], "issn-type": [{"value": "1538-4047", "type": "print"}, {"value": "1555-8576", "type": "electronic"}], "subject": ["Molecular Medicine", "Cancer Research", "Oncology", "Pharmacology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T07:17:39Z", "timestamp": 1574320659851}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 9, 1]], "date-time": "2009-09-01T00:00:00Z", "timestamp": 1251763200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2009, 9]]}, "DOI": "10.1016/s1359-6349(09)71208-x", "type": "journal-article", "created": {"date-parts": [[2009, 9, 3]], "date-time": "2009-09-03T12:23:03Z", "timestamp": 1251980583000}, "page": "356-357", "source": "Crossref", "is-referenced-by-count": 1, "title": ["6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients"], "prefix": "10.1016", "volume": "7", "author": [{"given": "C.", "family": "Cremolini", "sequence": "first", "affiliation": []}, {"given": "F.", "family": "Loupakis", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Perrone", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Ruzzo", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Rulli", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Bencardino", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Vincenzi", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Salvatore", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Graziano", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Falcone", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S135963490971208X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S135963490971208X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 17]], "date-time": "2018-12-17T11:21:04Z", "timestamp": 1545045664000}, "score": 34.89111, "issued": {"date-parts": [[2009, 9]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 9]]}, "issue": "2"}, "alternative-id": ["S135963490971208X"], "URL": "http://dx.doi.org/10.1016/s1359-6349(09)71208-x", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T18:25:45Z", "timestamp": 1574706345992}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl 4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Annals of Oncology"], "published-print": {"date-parts": [[2015, 6, 1]]}, "DOI": "10.1093/annonc/mdv234.13", "type": "journal-article", "created": {"date-parts": [[2015, 6, 24]], "date-time": "2015-06-24T12:54:48Z", "timestamp": 1435150488000}, "page": "iv105-iv105", "source": "Crossref", "is-referenced-by-count": 5, "title": ["PD-014 * First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)"], "prefix": "10.1093", "volume": "26", "author": [{"given": "F.", "family": "Rivera", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Karthaus", "sequence": "additional", "affiliation": []}, {"given": "J. R.", "family": "Hecht", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Fasola", "sequence": "additional", "affiliation": []}, {"given": "J.- L.", "family": "Canon", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Koukakis", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Demonty", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Schwartzberg", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2015, 6, 24]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/26/suppl_4/iv105/331969/mdv234.13.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 22]], "date-time": "2017-08-22T16:01:46Z", "timestamp": 1503417706000}, "score": 34.882217, "issued": {"date-parts": [[2015, 6, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2015, 6, 24]]}, "published-print": {"date-parts": [[2015, 6, 1]]}, "issue": "suppl 4"}, "URL": "http://dx.doi.org/10.1093/annonc/mdv234.13", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:15:44Z", "timestamp": 1574745344344}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "suppl_6", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016, 10]]}, "DOI": "10.1093/annonc/mdw370.33", "type": "journal-article", "created": {"date-parts": [[2017, 2, 3]], "date-time": "2017-02-03T17:10:54Z", "timestamp": 1486141854000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4"], "prefix": "10.1093", "volume": "27", "author": [{"given": "S.", "family": "Siena", "sequence": "first", "affiliation": []}, {"given": "F. Rivera", "family": "Herrero", "sequence": "additional", "affiliation": []}, {"given": "J-Y.", "family": "Douillard", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Taieb", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Koukakis", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Demonty", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Peeters", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2016, 10, 11]]}, "container-title": ["Annals of Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/annonc/article-pdf/27/suppl_6/485P/19450090/mdw370.33.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 9]], "date-time": "2017-08-09T05:31:30Z", "timestamp": 1502256690000}, "score": 34.8474, "issued": {"date-parts": [[2016, 10]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 10, 11]]}, "published-print": {"date-parts": [[2016, 10]]}, "issue": "suppl_6"}, "URL": "http://dx.doi.org/10.1093/annonc/mdw370.33", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T17:43:37Z", "timestamp": 1576777417562}, "reference-count": 42, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 3, 1]], "date-time": "2015-03-01T00:00:00Z", "timestamp": 1425168000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["ejcancer.info", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2015, 3]]}, "DOI": "10.1016/j.ejca.2015.01.054", "type": "journal-article", "created": {"date-parts": [[2015, 2, 9]], "date-time": "2015-02-09T04:15:14Z", "timestamp": 1423455314000}, "page": "587-594", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 178, "title": ["Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis"], "prefix": "10.1016", "volume": "51", "author": [{"given": "Filippo", "family": "Pietrantonio", "sequence": "first", "affiliation": []}, {"given": "Fausto", "family": "Petrelli", "sequence": "additional", "affiliation": []}, {"given": "Andrea", "family": "Coinu", "sequence": "additional", "affiliation": []}, {"given": "Maria", "family": "Di Bartolomeo", "sequence": "additional", "affiliation": []}, {"given": "Karen", "family": "Borgonovo", "sequence": "additional", "affiliation": []}, {"given": "Claudia", "family": "Maggi", "sequence": "additional", "affiliation": []}, {"given": "Mary", "family": "Cabiddu", "sequence": "additional", "affiliation": []}, {"given": "Roberto", "family": "Iacovelli", "sequence": "additional", "affiliation": []}, {"given": "Ilaria", "family": "Bossi", "sequence": "additional", "affiliation": []}, {"given": "Veronica", "family": "Lonati", "sequence": "additional", "affiliation": []}, {"given": "Mara", "family": "Ghilardi", "sequence": "additional", "affiliation": []}, {"given": "Filippo", "family": "de Braud", "sequence": "additional", "affiliation": []}, {"given": "Sandro", "family": "Barni", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804915000982?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804915000982?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 20]], "date-time": "2019-08-20T19:17:44Z", "timestamp": 1566328664000}, "score": 34.797623, "issued": {"date-parts": [[2015, 3]]}, "references-count": 42, "journal-issue": {"published-print": {"date-parts": [[2015, 3]]}, "issue": "5"}, "alternative-id": ["S0959804915000982"], "URL": "http://dx.doi.org/10.1016/j.ejca.2015.01.054", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Cancer", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejca.2015.01.054", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.", "name": "copyright", "label": "Copyright"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}